Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
WNBA will pay for flights for playoffs and backJustice Thomas misses Supreme Court session with no explanationShanghai to build complete care system for children with autism by 2027China's Han River sees first flood of 2024LaMelo Ball again considering ankle braces after injuries limited him to 58 games over two seasonsBoeing pushes back on whistleblower's allegations and details how airframes are put togetherZion Williamson, at long last, set to suit up for the Pelicans in the NBA postseasonIdaho can enforce ban on genderChina expects over 750 mln interJunta shelling, airstrikes kill 25 Rohingyas in Myanmar’s Rakhine state — Radio Free Asia
2.3417s , 6498.765625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Insights news portal